Anika Therapeutics(US:ANIK) Businesswire·2026-01-24 01:00Core Viewpoint - Anika Therapeutics, Inc. is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and other unlawful business practices related to its senior management [1]. Group 1: Company Performance - On July 30, 2025, Anika announced topline results from its clinical trial of Hyalofast, which is a resorbable hyaluronic acid scaffold for cartilage repair. The results indicated that while Hyalofast showed consistent improvements in treated patients compared to microfracture, it did not meet its pre-specified co-primary endpoints [2]. - The clinical trial's outcomes were likely affected by a higher dropout rate in the microfracture arm and missed visits during COVID, leading to missing data that complicated the statistical analysis [2]. - Following the announcement, Anika's share price fell by $3.06, or approximately 27.42%, closing at $8.10 per share on the same day [2]. Group 2: Legal Investigation - The ongoing investigation aims to determine if claims can be filed under federal securities laws, although no lawsuit has been initiated yet [3]. - Investors who purchased or acquired Anika securities and have relevant information are encouraged to contact Kirby McInerney LLP for further discussion regarding their rights or interests [3].